---
title: "Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293341740.md"
description: "On July 21, 2026, Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a leading biotech firm, shared their accomplishments and future goals for 2026. The company specializes in advanced genetic therapies."
datetime: "2026-07-21T12:10:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293341740.md)
  - [en](https://longbridge.com/en/news/293341740.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293341740.md)
---

# Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

On July 21, 2026, Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a leading biotech firm, shared their accomplishments and future goals for 2026. The company specializes in advanced genetic therapies.

### Related Stocks

- [CLDI.US](https://longbridge.com/en/quote/CLDI.US.md)

## Related News & Research

- [Calidi Biotherapeutics targets Q1 2027 clinic entry for CLD-401 cancer program](https://longbridge.com/en/news/293929420.md)
- [Calidi Biotherapeutics adds former Genentech, Celgene executive Corsee Sanders to board](https://longbridge.com/en/news/293337933.md)
- [Pacira transitions PCRX-201 gene therapy to scalable commercial manufacturing process in Phase 2 ASCEND study](https://longbridge.com/en/news/293929271.md)
- [Kyverna signs commercial manufacturing, supply deal with ElevateBio for miv-cel CAR-T therapy](https://longbridge.com/en/news/293928704.md)
- [10:31 ETFood Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight](https://longbridge.com/en/news/293947697.md)